Streetbeat News

TRUFF

Red Light Holland Corp

Industry

Other Food Crops Grown Under Cover

Open

0.03

Mkt cap

12M

Volume

39K

High

0.03

P/E Ratio

-3.00

52-wk high

0.06

Low

0.03

Div yield

N/A

52-wk low

0.02

Red Light Holland Corp. reported its Q2 2025 financial results, showing a cash balance of $13.5 million, increased revenues, and reduced EBITDA losses. The company, involved in the mushroom and psilocybin truffle market, saw a significant improvement in financial performance compared to 2023.

Portfolio Pulse from

November 29, 2024 | 12:45 pm

PharmAla Biotech has partnered with Johns Hopkins University to supply MDMA for clinical trials, marking a significant milestone for the company. They have also terminated their contract with Red Light Holland, indicating a strategic shift. Additionally, PharmAla will present research on their proprietary molecule APA-01 at an upcoming workshop.

Portfolio Pulse from Juan Spínelli

September 11, 2024 | 5:08 pm

Red Light Holland Corp. reported a 29.7% year-over-year increase in Q1 2025 revenue, reaching CA$1.5 million. The company focuses on functional mushrooms and psilocybin truffles, with a strategic aim towards profitability. Despite a net loss of CA$1.4 million, the company maintains a strong cash position.

Portfolio Pulse from Jelena Martinovic

August 30, 2024 | 1:40 pm

PATOO, a Jamaica-based psychedelic CPG brand, has partnered with Fontana Pharmacy to introduce the first legal psilocybin-infused products to Jamaican pharmacy shelves. This move marks a significant step toward broader acceptance of psychedelic wellness products. Several publicly traded companies are at the forefront of developing and commercializing psychedelic therapies, including Compass Pathways, Atai Life Sciences, Cybin Inc., Mind Medicine, Mydecine Innovations Group, Seelos Therapeutics, and Revive Therapeutics.

Portfolio Pulse from Javier Hasse

July 31, 2024 | 12:00 pm

Red Light Holland Corp. (OTCQB:TRUFF) reported a 20.3% YoY revenue growth for FY 2024, reaching CA$4.7 million. Despite a net loss of CA$7.71 million, the company remains focused on long-term profitability and advocacy for psilocybin access. Shares closed 2.78% lower at $0.035.

Portfolio Pulse from Nina Zdinjak

July 30, 2024 | 12:25 pm

Red Light Holland Corp. and PharmAla Biotech Holdings Inc. have successfully completed the first phase of psilocybin extraction, marking a significant milestone in their collaboration. The companies aim to produce naturally derived Active Pharmaceutical Ingredients (API) from psilocybin truffles at a commercial scale. The next steps involve optimizing and validating the extraction process.

Portfolio Pulse from Patricio Liddle

May 29, 2024 | 8:27 pm

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

The article provides a comprehensive roundup of recent developments in the psychedelics sector, highlighting research findings, regulatory updates, and industry movements. Key highlights include the launch of Usona Institute's Phase 3 clinical trial on psilocybin for Major Depressive Disorder, partnerships for psilocybin research, and significant corporate changes within companies like Compass Pathways and Cybin. Additionally, several companies announced progress in clinical trials, patent approvals, and expansions in product distribution.

Portfolio Pulse from Lara Goldstein

March 30, 2024 | 12:57 pm

Cybin Inc. received FDA Breakthrough Therapy designation for its psilocybin therapy for Major Depressive Disorder, alongside positive clinical data and a $150M private placement. MindMed also received the designation for its LSD-derived treatment for Generalized Anxiety Disorder, with expected proceeds of $175M from share offerings. Gilgamesh Pharmaceuticals was awarded a $14M grant for ibogaine analog research. Psyence Biomedical, Red Light Holland, and Clearmind Medicine were mentioned for their developments in psychedelics. The article also covered stock performances of several psychedelics companies.

Portfolio Pulse from Lara Goldstein

March 20, 2024 | 6:49 pm

Clinical trials show psilocybin-assisted therapy's potential for treating Generalized Anxiety Disorder. Incannex Healthcare (NASDAQ:IXHL) conducted the Phase 2 study. Enveric Biosciences (NASDAQ:ENVB) announced non-binding deals to license drug compounds for mental health treatments. Compass Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), MindMed (NASDAQ:MNMD), and other companies reported financial results and business updates. AdvisorShares Psychedelics ETF (NYSE:PSIL) and several US-listed companies showed varied stock performance.

Portfolio Pulse from Lara Goldstein

March 04, 2024 | 6:48 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.